British Innovation Shines at the iawards
A tool that identifies personalised cancer medications - reducing R&D costs, shortening clinical cycles and increasing patient survival. Chairman of QinetiQ, Sir John Chisholm said: "We had an extremely high calibre of entries but this product really stood out for us. The Horizon cell model represents first class innovation and we should be proud that a British company is helping lead the way in the fight against cancer. A truly deserving winner - and one that can positively affect many lives." Chair judge, Mike Butcher said: "Horizon Discovery really impressed us with their 'patient in a test-tube', which is the first human cell model that can identify personalised cancer medications, leading to shorter drug trials and increased patient life. Quite simply, this is world-class scientists doing first-class work. They have developed a revolutionary approach and demonstrated clever innovation in a difficult area, with excellent prospects for impact on the health sector." For further information and videos, pelase visit:
http://www.iawards.org.uk